8.0361
Precedente Chiudi:
$7.67
Aprire:
$7.61
Volume 24 ore:
514.64K
Relative Volume:
0.37
Capitalizzazione di mercato:
$464.75M
Reddito:
$65,400
Utile/perdita netta:
$-46.34M
Rapporto P/E:
-8.7349
EPS:
-0.92
Flusso di cassa netto:
$-38.74M
1 W Prestazione:
+12.69%
1M Prestazione:
-26.35%
6M Prestazione:
-28.26%
1 anno Prestazione:
+52.18%
CorMedix Inc Stock (CRMD) Company Profile
Nome
CorMedix Inc
Settore
Industria
Telefono
908-517-9500
Indirizzo
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Confronta CRMD con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CRMD
CorMedix Inc
|
8.01 | 464.75M | 65,400 | -46.34M | -38.74M | -0.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
481.65 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.58 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
602.80 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
233.64 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-07 | Iniziato | Leerink Partners | Outperform |
2025-01-13 | Iniziato | D. Boral Capital | Buy |
2024-08-26 | Iniziato | Rodman & Renshaw | Buy |
2023-08-10 | Iniziato | RBC Capital Mkts | Outperform |
2021-02-17 | Iniziato | Needham | Buy |
2020-09-29 | Iniziato | JMP Securities | Mkt Outperform |
2020-09-21 | Iniziato | Truist | Buy |
2019-12-18 | Iniziato | B. Riley FBR | Buy |
2019-03-26 | Reiterato | H.C. Wainwright | Buy |
2018-12-06 | Iniziato | ROTH Capital | Buy |
2017-09-25 | Reiterato | H.C. Wainwright | Buy |
2017-08-10 | Reiterato | Rodman & Renshaw | Buy |
2017-05-05 | Reiterato | Rodman & Renshaw | Buy |
2016-11-11 | Reiterato | FBR & Co. | Outperform |
2016-03-17 | Reiterato | FBR Capital | Outperform |
2016-03-03 | Iniziato | FBR Capital | Outperform |
2015-11-16 | Reiterato | ROTH Capital | Neutral |
2015-10-29 | Reiterato | ROTH Capital | Neutral |
2015-05-06 | Downgrade | ROTH Capital | Buy → Neutral |
2014-12-08 | Reiterato | ROTH Capital | Buy |
2011-10-03 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
CorMedix Inc Borsa (CRMD) Ultime notizie
Investors in CorMedix (NASDAQ:CRMD) have seen decent returns of 81% over the past five years - Yahoo Finance
RBC stays bullish on CorMedix as Q1 preliminary revenue reassures on near-term - Yahoo Finance
CorMedix expects Q1 sales above estimates, lifts H1 outlook - MSN
CorMedix reports preliminary Q1 revenue $39M, consensus $32.2M. - TipRanks
CorMedix at Needham Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
CorMedix at Needham Conference: Strategic Growth and Challenges - Investing.com
CorMedix Stock Rises After Preliminary Q1 Results Exceeds Expectations: Retail’s Elated - MSN
CRMD Soars 19.40% as CorMedix Announces Preliminary Q1 Results and Raises H1 Guidance, But Will the Momentum Continue? - RagingBull
CorMedix Inc. Raises Financial Guidance for First Half of 2025 - MarketScreener
CorMedix Sees Q1 Net Sales of $39 Million; Boosts H1 Net Sales Guidance - MarketScreener
Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance - The Manila Times
CorMedix Logs Q1 Prel. Revenue Of $39 Mln - Nasdaq
CorMedix reports strong preliminary Q1 revenue and EBITDA - Investing.com
CorMedix Smashes Expectations: $39M Q1 Revenue and Massive Guidance Boost Signals Growth Acceleration - Stock Titan
CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
CorMedix CEO Sets Stage for Strategic Updates at Elite Needham Healthcare Conference - Stock Titan
CorMedix Inc. (NASDAQ:CRMD) Q4 2024 Earnings Call Transcript - Insider Monkey
CorMedix Inc. Reports Record Q4 Earnings and Growth - TipRanks
CorMedix: A Fair-Priced Biotech Company With A Bright Future - Seeking Alpha
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of ... - Bluefield Daily Telegraph
Institutions along with individual investors who hold considerable shares inCorMedix Inc. (NASDAQ:CRMD) come under pressure; lose 35% of holdings value - Yahoo Finance
CorMedix targets $50M-$60M revenue for H1 2025 with DefenCath growth - MSN
CorMedix Inc.'s (NASDAQ:CRMD) 35% loss last week hit both individual investors who own 56% as well as institutions - simplywall.st
Lost Money on CorMedix Inc.(CRMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Kirby McInerney LLP Announces Investigation Against CorMedix Inc. (CRMD) on Behalf of Investors - GlobeNewswire
The Hidden Risks Behind CorMedix's First Profitable Quarter (NASDAQ:CRMD) - Seeking Alpha
CorMedix Inc (NASDAQ:CRMD) Order Delay - FXDailyReport.Com
Long Term Trading Analysis for (CRMD) - news.stocktradersdaily.com
INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC - GlobeNewswire
CorMedix Inc. (CRMD) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates - Louisiana First News
Cormedix Inc (CRMD) Q4 2024 Earnings Call Highlights: A Profitable Quarter Amidst Strategic ... By GuruFocus - Investing.com Canada
CorMedix Inc. Achieves Profitability with DefenCath Launch - TipRanks
Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target By Investing.com - Investing.com Australia
CorMedix: Q4 Earnings Snapshot - MySA
Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target - Investing.com
CorMedix (CRMD) Q4 2024 Earnings Call Transcript - AOL.com
CorMedix earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Needham Cuts CorMedix's Price Target to $12 from $18, Keeps Buy Rating - MarketScreener
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It - Asianet Newsable
Cormedix: Positive Outlook with Strategic Advancements and Strong Financial Performance - TipRanks
CorMedix Inc. (CRMD) Takes a Hit: What’s Behind the 31% Plunge? - RagingBull
Nasdaq Gains 50 Points; US New Home Sales Rise In February - Benzinga
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It Off - MSN
Earnings call transcript: CorMedix Q4 2024 reports first profit, stock plunges - Investing.com Australia
CorMedix shares tumble after order delay By Investing.com - Investing.com Philippines
CorMedix shares tumble after order delay - Investing.com
CorMedix Inc Azioni (CRMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):